Pressure therapy upregulates matrix metalloproteinase expression and downregulates collagen expression in hypertrophic scar tissue

Chinese Medical Journal

Volumn 126, Issue 17, 2013, Pages 3321-3324

  Huang, Dong ^a   Shen, Kuan Hong ^b   Wang, Hong Gang ^c  

^a GUANGDONG SECOND PROVINCIAL GENERAL HOSPITAL   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Collagen; Fibroblast; Hypertrophic scar; Matrix metalloproteinase; Pressure therapy

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COMPLEMENTARY DNA; GELATINASE A; GELATINASE B; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXPERIMENTAL DESIGN; FIBROBLAST; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTROPHIC SCAR; PRESSURE THERAPY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WOUND CARE;

CELL LINE; CICATRIX, HYPERTROPHIC; COLLAGEN TYPE I; HUMANS; MATRIX METALLOPROTEINASE 12; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9;

EID: 84883512017     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20130833     Document Type: Article

References (21)

1. Xiao Z, Zhang M, Liu Y, Ren L. Botulinum toxin type a inhibits connective tissue growth factor expression in fibroblasts derived from hypertrophic scar. Aesthetic Plast Surg 2011; 35: 802-807.
2. Tuan TL, Nichter LS. The molecular basis of keloid and hypertrophic scar formation. Mol Med Today 1998; 4: 19-24.
3. Miller MC, Nanchahal J. Advances in the modulation of cutaneous wound healing and scarring. BioDrugs 2005; 19: 363-381.
4. Wang ZY, Zhang J, Lu SL. Objective evaluation of burn and post-surgical scars and the accuracy of subjective scar type judgment. Chin Med J 2008; 121: 2517-2520.
5. Shi JH, Hu DH, Zhang ZF, Bai XZ, Wang HT, Zhu XX, et al. Reduced expression of microtubule-associated protein 1 light chain 3 in hypertrophic scars. Arch Dermatol Res 2012; 304: 209-215.
6. Li JQ, Li-Tsang CW, Huang YP, Chen Y, Zheng YP. Detection of changes of scar thickness under mechanical loading using ultrasonic measurement. Burns 2013; 39: 89-97.
7. Steinstraesser L, Flak E, Witte B, Ring A, Tilkorn D, Hauser J, et al. Pressure garment therapy alone and in combination with silicone for the prevention of hypertrophic scarring: randomized controlled trial with intraindividual comparison. Plast Reconstr Surg 2011; 128: 306e-313e.
8. Penn JW, Grobbelaar AO, Rolfe KJ. The role of the TGF-β family in wound healing, burns and scarring: a review. Int J Burns Trauma 2012; 2: 18-28.
9. Ward SV, Cadby G, Heyworth JS, Fear MW, Wallace HJ, Cole JM, et al. Association of TGFβ1 and clinical factors with scar outcome following melanoma excision. Arch Dermatol Res 2012; 304: 343-351.
10. Subramaniam K, Pech CM, Stacey MC, Wallace HJ. Induction of MMP-1, MMP-3 and TIMP-1 in normal dermal fibroblasts by chronic venous leg ulcer wound fluid. Int Wound J 2008; 5: 79-86.
11. Ghahary A, Shen YJ, Nedelec B, Wang R, Scott PG, Tredget EE. Collagenase production is lower in post-burn hypertrophic scar fibroblasts than in normal fibroblasts and is reduced by insulin-like growth factor-1. J Invest Dermatol 1996; 106: 476-481.
12. Mwaura B, Mahendran B, Hynes N, Defreitas D, Avalos G, Adegbola T, et al. The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers. Eur J Vasc Endovasc Surg 2006; 31: 306-310.
13. Abergel RP, Pizzurro D, Meeker CA, Lask G, Matsuoka LY, Minor RR, et al. Biochemical composition of the connective tissue in keloids and analysis of collagen metabolism in keloid fibroblast cultures. J Invest Dermatol 1985; 84: 384-390.
14. Castro DJ, Abergel RP, Meeker C, Dwyer RM, Lesavoy MA, Uitto J. Effects of the Nd:YAG laser on DNA synthesis and collagen production in human skin fibroblast cultures. Ann Plast Surg 1983; 11: 214-222.
15. Xie XF, He LX, Hao XF, Chen B, Jia CY, Sun ZG, et al. Expression of matrix metalloproteinase-2,-9 and their inhibitor-1 in hypertrophic scars. Chin J Burns (Chin) 2007; 23: 444-446.
16. Ulrich D, Ulrich F, Unglaub F, Piatkowski A, Pallua N. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with different types of scars and keloids. J Plast Reconstr Aesthet Surg 2010; 63: 1015-1021.
17. Ulrich D, Noah EM, von Heimburg D, Pallua N. TIMP-1, MMP-2, MMP-9, and PIIINP as serum markers for skin fibrosis in patients following severe burn trauma. Plast Reconstr Surg 2003; 111: 1423-1431.
18. Gupta S, Sharma VK. Standard guidelines of care: Keloids and hypertrophic scars. Indian J Dermatol Venereol Leprol 2011; 77: 94-100.
19. Alster TS, Tanzi EL. Hypertrophic scars and keloids: etiology and management. Am J Clin Dermatol 2003; 4: 235-243.
20. Didangelos A, Yin X, Mandal K, Saje A, Smith A, Xu Q, et al. Extracellular matrix composition and remodeling in human abdominal aortic aneurysms: a proteomics approach. Mol Cell Proteomics 2011; 10: M111.008128.
21. Liang YH, Li P, Zhao JX, Dai MK, Huang QF. Arsenic trioxide regulates the production and activities of matrix metalloproteinases-1,-2, and-9 in fibroblasts and THP-1. Chin Med J 2012; 125: 4481-4487.